Filters
Non-Hodgkin lymphoma seems to worsen cognitive performance in elderly adults, especially in the domains of attention, a recent study reveals.
Adding a yoga regimen to medical therapy reduced the frequency and intensity of headaches among patients with episodic migraine, according to results of the CONTAIN trial.
Patients using the CGRP* blocker fremanezumab for migraine treatment need not worry about cardiovascular (CV) safety of the drug, as pooled data from three phase III trials showed no safety signals for CV events with the treatment, even in those with a CV medical history.
Pinch strength is an independent predictor of mild cognitive impairment (MCI) in patients with cardiovascular diseases (CVDs), a recent study has found.
Sociodemographic factors appear to be important determinants of time to epilepsy surgery for children with focal cortical dysplasia, a new study has shown.
New drug applications approved by US FDA as of 16 - 31 May 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Patients with chronic pain are at increased risk of developing major adverse cardiac and cerebrovascular events (MACCEs), according to a study.
Cognitive training interventions help ameliorate depression symptoms in older adults with mild cognitive impairment or dementia, according to the results of a meta-analysis.
Higher cardiovascular risk burden correlates with neurodegeneration and vascular lesions in the brain and appears to be a predictor of decline in episodic memory, working memory, and perceptual speed, a study has shown.
Mood, physical function, learning, and memory are important correlates of health-related quality of life (HRQoL) in patients with metastatic brain cancer, a new study has found.